LPTX 2.66 Leap Therapeutics, Inc.
| Range: | 1.311-5.0 | Vol Avg: | 115617 | Last Div: | 0 | Changes: | 0.35 |
| Beta: | 0.27 | Cap: | 0.10B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jan 25 2017 | Empoloyees: | 54 | ||
| CUSIP: | 52187K101 | CIK: | 0001509745 | ISIN: | US52187K2006 | Country: | US |
| CEO: | Mr. Douglas E. Onsi J.D. | Website: | https://www.leaptx.com | ||||
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Stock Details
LPTX 5.5
Leap Therapeutics price target lowered to $5.50 from $7 at H.C. Wainwright
Swayampakula Ramakanth·Tue May 14 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow